Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Friday

Key Points

• Tonix Pharmaceuticals is expected to announce its Q1 2025 earnings on August 15th, projecting a loss of ($6.71) per share with $2.60 million in revenue.
• The company recently reported a quarterly loss of ($2.84) EPS, beating estimates, but had a significantly negative return on equity of 120.96%.
• Insider CEO Seth Lederman purchased 4,000 shares at $21.55 each, significantly increasing his ownership stake as institutional investors hold 82.26% of the stock.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) is projected to announce its Q1 2025 earnings results before the market opens on Friday, August 15th. Analysts expect Tonix Pharmaceuticals to post earnings of ($6.71) per share and revenue of $2.60 million for the quarter.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.23) by $0.39. The firm had revenue of $2.43 million during the quarter, compared to analyst estimates of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 120.96% and a negative net margin of 1,313.87%. On average, analysts expect Tonix Pharmaceuticals to post $-1,763 EPS for the current fiscal year and $-542 EPS for the next fiscal year.

Tonix Pharmaceuticals Trading Up 2.8%

Shares of Tonix Pharmaceuticals stock opened at $46.92 on Friday. The firm has a market cap of $345.33 million, a P/E ratio of -0.02 and a beta of 1.70. The stock's fifty day moving average price is $39.63 and its 200-day moving average price is $26.60. Tonix Pharmaceuticals has a 12 month low of $6.76 and a 12 month high of $130.00.

Insiders Place Their Bets

In other news, CEO Seth Lederman acquired 4,000 shares of Tonix Pharmaceuticals stock in a transaction dated Thursday, May 15th. The stock was purchased at an average cost of $21.55 per share, for a total transaction of $86,200.00. Following the completion of the purchase, the chief executive officer directly owned 4,005 shares in the company, valued at $86,307.75. This trade represents a 80,000.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.03% of the company's stock.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. Royal Bank of Canada bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 34,153 shares of the company's stock, valued at approximately $610,000. Royal Bank of Canada owned 0.53% of Tonix Pharmaceuticals at the end of the most recent reporting period. 82.26% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on TNXP shares. Wall Street Zen upgraded Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. Alliance Global Partners restated a "buy" rating on shares of Tonix Pharmaceuticals in a research note on Tuesday, June 3rd.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.